In Ethnobridging, News

Orlando, FL / April 3, 2008 /
WCCT is pleased to announce the presentation of one of the largest Asian bridging trials done by a single site at this year’s American Society of Clinical Pharmacology annual meeting in Orlando, Florida titled, “INCREASED SYSTEMIC EXPOSURE TO ROSUVASTATIN IN ASIAN SUBJECTS RESIDING IN THE UNITED STATES COMPARED TO CAUCASIAN SUBJECTS” The study involved enrolling 27 Japanese, 26 Chinese, 25
Vietnamese, 26 Korean, 26 Asian Indian, and 26 Caucasians, and demonstrated approximately double the area under the curve (AUC) for all Asian subgroups which
was intermediate as compared to the Caucasian reference group. As a result of this study and several other earlier studies, the dosing recommendations for rosuvastatin is recommended to be
half of the dose recommended for Caucasians. WCCT, a phase I CRO with a special strength in recruiting Asian subpopulations, is particularly well situated to enroll any Asian subpopulation based on it’s location in the Los Angeles metropolitan
area, home to large populations of ethnic Chinese, Japanese, Asian Indians, Cambodians, Vietnamese, and Koreans within a 30 mile radius of the site.

About West Coast Clinical Trials, LLC

WCCT is an independent early phase clinical CRO with a 120-bed phase I facility with 10 telemetry equipped beds located in southern California. WCCT has a unique focus on Ethno-bridging studies along with extensive experience with healthy volunteer and specialty trials (allergy, asthma, infectious disease, pediatric, renal and vaccines). For more information, visit our Web site at



West Coast Clinical Trials
5630 Cerritos Ave.
Cypress, CA 90630 USA
Phone: (714) 252-0700

Start typing and press Enter to search